sis, 14 and disease recurrence. 15 The use of immunosuppressive medication and comorbidities including obesity, metabolic syndrome, and subsequent malignancies may also contribute to a decreased survival of OLT recipients. 16 However, the influence of many other factors on long-term survival outcomes after OLT are still unknown.
One of these factors could be muscle mass, an important source of amino acids and a key player in protein metabolism, which, in turn, is of key importance in the stress response. 17 Previous studies have shown that low muscle mass is an independent predictor of survival in several chronic diseases, including heart failure and cancer. 18, 19 Moreover, it is well established that muscle mass is an indicator of nutritional status in patients who suffer from protein-energy malnutrition. 20 It has also been demonstrated that protein-energy malnutrition is associated with a higher risk of mortality in patients awaiting OLT. 21 Pretransplant muscle mass, as measured by computed tomography (CT), predicts intensive care unit (ICU) total length of stay and days of intubation after OLT. 22 However, the role of posttransplant low muscle mass has not yet been studied on long-term patient and graft survival outcomes in OLT recipients.
Creatinine is a breakdown product of creatine phosphate in muscle, which is usually produced at a constant rate depending on the amount of muscle mass. 23 Urinary creatinine excretion rate (CER) is therefore an established marker of total body muscle mass in diverse populations, including patients with wasting condition. [24] [25] [26] [27] Low muscle mass, or sarcopenia, is an important comorbid condition in OLT recipients; however, studies investigating urinary CER have not yet been performed. We hypothesized that low urinary CER was associated with poor long-term survival after OLT. Therefore, the aim of this study was to determine whether CER is a prognostic marker of mortality and graft failure in stable OLT recipients.
| MATERIAL S AND ME THODS

| Study design and population
A single center retrospective analysis was performed in all patients aged ≥ 18 years who underwent OLT at the University Medical
Center Groningen, the Netherlands, between January 1993 and December 2010. All patients received care according to a standardized protocol. Baseline was set at 1 year posttransplantation, because recipients are then considered to be stable and are less likely to develop rejection or infections. OLT recipients with missing baseline data on CER, those with a (graft) survival time less than 1 year, and those lost to follow-up were excluded.
According to the Dutch law, general consent for transplantation and organ donation includes consent for research projects. The study protocol was approved by the institutional research board (METc 2014/77) and adhered to the Declaration of Helsinki as well as to the Declaration of Istanbul on Organ Trafficking and Transplant Tourism.
| Data collection and measurements
Data were retrieved from electronic patient records. Weight, height, etiology, blood pressure, medication, and smoking status were derived from patients records. Body mass index (BMI) was defined as weight divided by height squared (kg/m 2 ). Body surface area (BSA)
was assessed using the DuBois formula. 28 A positive cardiovascular history was defined as a previous myocardial infarction, cerebrovascular accident, and/or peripheral arterial disease. Donor characteristics were collected using the Eurotransplant database.
To obtain adequate 24 h urine samples all patients were required to adhere to a standardized protocol. All patients were instructed to start by discarding the urine void at the start of collection and to subsequently collect all urine for the next 24 hours, including a void at precisely 24 hours after the collection start. To minimize collection and measurement errors, a median of all laboratory and 24 h urinary measurements between 9 and 15 months posttransplantation was calculated ( Figure   S1 ). The median of these measurements was used for analyses. CER, urinary urea excretion, and proteinuria were assessed from 24 h urine collection. Proteinuria was defined as urinary protein excretion of > 0.5 g/ day. Data on glucose, total cholesterol, triglycerides, C-reactive protein, hemoglobin levels, aspartate transaminase (AST), alanine transaminase (ALT), gamma-glutamyltransferase (γ-GT), alkaline phosphatase (ALP), direct and total bilirubin, serum albumin, and serum creatinine were extracted from the hospital laboratory system. The estimated glomerular filtration rate (eGFR) was calculated using the Chronic Kidney Disease
Epidemiology Collaboration (CKD-EPI) equation. 29 To assess a potential time effect, transplantation dates were divided into 3 consecutive eras based on changes in immunosuppressive regimens. The first era was set from 1993 until 1998, the second era from 1999 until 2004, and the third era from 2005 until 2010.
| Immunosuppressive regimens and rejection
Immunosuppressive therapy was given according to a standardized protocol. Generally, from 1993 therapy consisted of a combination of prednisolone (10 mg/day), azathioprine (125 mg/day), and cyclosporin A, resulting in whole-blood levels of ~100 μg/L in the first year posttransplantation. From 1998 onwards, immunosuppressive therapy consisted of a combination of prednisolone and tacrolimus (whole-blood levels in the first year between 5-7 μg/L) or a combination of prednisolone, cyclosporin A, and azathioprine. From April 2010, the combination of prednisolone, mycophenolate mofetil, and tacrolimus was used by default. Variations in the standard regimens were present and were related to side effects or treatment of allograft rejection. 30,31. Acute rejection was diagnosed either clinically or confirmed with a biopsy. If acute rejection was present, initial therapy was to optimize levels of tacrolimus. If acute rejection persisted, therapy consisted of 1000 mg methylprednisolone for 3 consecutive days.
Cumulative dose of prednisolone was calculated by multiplying the prednisolone dose at baseline by the time since transplantation and adding the dose of prednisolone or methylprednisolone required for treatment of acute rejection. A conversion factor of 1.25 was used to convert methylprednisolone dose to prednisolone dose.
| Outcome measures
The primary outcome of this study was all-cause mortality. The secondary outcomes of this study were death-censored graft failure and cause-specific mortality, divided into four categories: cardiovascular, infectious, malignancy, and miscellaneous. Death-censored graft failure was defined as the requirement for retransplantation.
Data on cause-specific mortality were derived from electronic patient records or, in case of missing data, requested from general practitioners. Follow-up was recorded up to 15 years after baseline, or until December 31, 2016. 
| Statistical analysis
| RE SULTS
| Baseline characteristics
Between 1993 Table 1 . OLT recipients in the lowest tertile were significantly older, smoked more frequently, and were smaller when compared to OLT recipients in the highest tertile. Furthermore, patients in the lowest tertile had a lower body weight, lower BMI, lower BSA, higher total cholesterol, lower hemoglobin, and lower albumin levels when compared to patients in the highest tertile. Moreover, liver enzymes were significantly higher in OLT recipients in the lowest tertile when compared to OLT recipients in the highest tertile. Lastly, cumulative dose of prednisolone was lower in patients in the lowest tertile compared to patients in the highest tertile, whereas prednisolone dose at baseline and number of OLT recipients using prednisolone at baseline did not differ. There were no differences in renal function, transplant characteristics, and use of medication other than prednisolone. The median CER according to categories of primary liver disease for the overall OLT recipient population and according to sex stratified tertiles of CER is shown in Table 2 . No material differences in CERs were observed between the primary liver diseases.
TA B L E 1 Baseline characteristics of the overall OLT recipient population and according to sex-stratified tertiles of creatinine excretion rate Figure 1A , log-rank test: P = .009). For death-censored graft failure, 17 (13.4%) OLT recipient needed retransplantation in the first tertile, whereas 17 (13.3%) and 10 (7.9%) OLT recipients needed retransplantation in respectively the second and third tertile ( Figure 1B , log-rank test:
We proceeded with Cox regression analyses and checked for -test for categorical variables. Cardiovascular disease history was defined as myocardial infarction, cerebrovascular accident and/or peripheral arterial disease. BMI, body mass index; BSA, body surface area; SBP, systolic blood pressure; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HDL-cholesterol, high-density lipoprotein; CRP, C-reactive protein; AST, aspartate aminotransferase; ALT, alanine aminotransferase; γ-GT, gamma-glutamyltransferase; ALP, alkaline phosphatase; NASH, non-alcoholic fatty liver disease. Storage disorders include Wilson's disease, hemochromatosis and alfa-1-antitrypsin deficiency. Hypertension was defined as a SBP ≥ 140 mmHg and/or a DBP ≥ 90 mmHg and/ or the use of antihypertensive drugs; Antidiabetics include oral agents and insulin.
TA B L E 1 (Continued)
all-cause mortality and death-censored graft failure no significant interactions were identified (all P ≥ .05), when adjusted for age, sex, and BSA. (Table 3 , models 4-7) or death-censored graft failure (Table 4 , models 4-5).
We continued with Cox proportional-hazards models to study the associations according to tertiles of CER. OLT recipients with low CER levels (first tertile) appeared to be at an approximately 2.5-fold higher risk of all-cause mortality (HR = 2.58; 95% CI: 1.35-4.93, P = .004), and 3-fold higher risk of graft failure (HR = 3.20; 95% CI:
1.21-8.44, P = .02), when compared to OLT recipients in the third tertile, independent of potential confounders including age, sex, BSA, eGFR, proteinuria, primary liver disease, and transplantation era (Table 3 , model 3). Adjusting for other potential confounders did not materially change the results for all-cause mortality and graft failure ( Table 3 , models 4-7; Table 4 , models 4-5).
To investigate the association of CER with cause-specific mortality, we performed additional Cox regression analyses (Table   S1 ). We found a significant association of CER with cardiovascular mortality (model 3, HR 0.77; 95% CI 0.66-0.89, P < .001). No statistically significant associations were found for CER with infectious, malignant, and miscellaneous mortality. Furthermore, there was a significant association of CER around 6 months posttransplantation with all-cause mortality (model 3, HR: 0.54; 95% CI: 0.33-0.88, P = .01), which was independent of age, sex, BSA, eGFR, proteinuria, primary liver disease, and transplantation era.
We did not find a significant association of CER around 6 months after transplantation with graft failure (Table S2) . Additional analyses were performed to assess the association of change in CER with all-cause mortality and death-censored graft failure (Table S3 ).
Change in CER was not predictive for all-cause mortality, whereas CER measured at 1 year posttransplant and 6 months posttransplant were. However, change in CER was predictive for graft failure, whereas CER at 6 months posttransplant was not. When comparing the magnitude of CER with other potential variables of interest additional Cox regression analyses revealed muscle mass to have a similar magnitude for the association with mortality as glucose and BMI (Table S4 ).
| D ISCUSS I ON
In this study, we demonstrated that a low posttransplant total body muscle mass, as measured by urinary CER, was inversely associated with an increased risk of long-term all-cause mortality and graft failure in OLT recipients. The risk for all-cause mortality was more than 2.5-fold higher and the risk for death-censored graft failure was 3-fold higher in the lowest tertile when compared to the highest tertile of CER. The current results underline the importance of an adequate posttransplant total body muscle mass on long-term survival post-OLT.
To the best of our knowledge, we are the first to investigate the association of posttransplant total body muscle mass, as reflected by urinary CER, with long-term all-cause mortality and graft failure in OLT recipients. Urinary CER is an inexpensive, accessible, Muscle mass, as reflected by CER, has been associated with the development of cardiovascular disease and all-cause mortality in the general population. 24 As mentioned, OLT recipients have about 20% reduced survival rates when compared to the general population. 5 This magnitude of survival rate was similar for OLT recipients in the third tertile in our study. However, a decrease of almost 30%
in survival rate was observed in OLT recipients in the first tertile, emphasizing the importance of muscle mass for OLT recipients.
Results in the general population are consistent with the results from other populations, namely that CER has been associated with mortality, independently of age and sex in patients with coronary artery disease, type 2 diabetes, and heart failure. 26, 32, 33 In addition, CER has been shown to predict all-cause mortality and graft failure in renal transplant recipients, implicating the importance of muscle mass posttransplantation. 
Survival (%)
To date, focus has predominantly been on pretransplant muscle mass and its effect on adverse outcomes post-transplantation. Yet, we would advocate that attention on muscle mass, the anabolic influence of dietary interventions, and physical activity on longer term posttransplantation is warranted. Regrettably, CT is usually not part of routine posttransplantation follow-up. Moreover, it requires exposure to radiation, is expensive, and like magnetic resonance imaging (MRI), does not allow for whole body muscle mass measurement, which is reflected by CER. In addition, CT and MRI measurements may lead to over-or underestimation of muscle mass. CT and MRI lack the capability for specific tissue differentiation between edema and fatty infiltration in muscle mass, which could lead to overestimation. On the other hand, in wasting conditions connective, neural, and vascular tissue do not atrophy as much as muscle mass, which in turn could lead to underestimation.
23,34
TA B L E 3 Association of creatinine excretion rate with all-cause mortality (12- Sarcopenia or loss of skeletal muscle mass is the major component of malnutrition and is a frequent complication in chronic liver disease and cirrhosis that adversely affects clinical outcomes. 35 Because etiology and severity of the underlying liver disease may significantly contribute to the severity of loss of skeletal muscle mass, 35 it could be hypothesized that these patients have different levels of urinary CER posttransplantation. In our study, levels of posttransplant CER did not differ across categories of primary liver disease, indicating that disease etiology was not associated with skeletal muscle mass status, as measured by urinary CER 1 year posttransplantation.
Liver transplantation is expected to abolish the abnormalities in nutritional status and in dietary intake. By restoring liver function, maintenance of protein synthesis and the liver's ability to regulate energy metabolism is recovered, presumably eliminating the metabolic alterations involved in the pathophysiology of malnutrition in cirrhotic patients. 36 Nonetheless, status after transplantation is associated with accelerated senescence, making OLT recipients prone to muscle wasting. 37 Unfortunately, meticulous evaluation of mechanisms responsible for loss of muscle mass has not yet been performed. As a result, protein-energy malnutrition can still be observed in OLT recipients, greatly increasing recipients risks for mortality. 21, 38 Although the impact of posttransplantation malnutrition on graft failure has not yet been studied in OLT recipients and a potential mechanism is unknown, protein-energy malnutrition has been associated with graft loss in renal transplant recipients. 39 In this study, causal pathway analyses revealed muscle mass to be an explanatory component. Therefore, we hypothesize that proteinenergy malnutrition may also increase the risk for graft loss in OLT recipients.
Although muscle mass is often not regained posttransplantation, a substantial increase in body weight can be observed. Most
OLT recipients gain an average of 5.1 kg, in the first year posttransplantation. 40 This gain of mostly fat mass increases in subsequent years and is accelerated by poor lifestyle factors, including an approximately doubled fat intake compared to pretransplantation, reduced physical activity, and immunosuppressive medication. [40] [41] [42] As a result, an increased prevalence of obesity and new onset diabetes after transplantation, and an increased risk of metabolic syndrome and mortality in OLT recipients can be observed. 40, 43, 44 As mentioned, OLT recipients have reduced levels of physical activity compared with age-predicted levels in healthy populations. 45, 46 Physical activity has a large impact on weight management and is known to improve exercise capacity and muscular strength. 46 The latter has been shown to be inversely associated with hypertension in OLT recipients and mortality in cirrhotic patients. 47, 48 Furthermore, the same entities that could lead to a poor muscle mass are suspected to give rise to low physical activity. Hence, muscle mass could be an indirect measure of physical activity and therefore explain the results found in this study. Management of impaired muscle mass should ideally be initiated as soon as possible after recovery from transplantation. However, to the best of our knowledge, studies on nutritional and physical-activity-based interventions to regain muscle mass and improve long-term outcome are lacking. 49 Nevertheless, there are some studies that show the effects of nutrition and physical activity on short-term outcomes. A previous retrospective study showed that perioperative nutritional therapy improved short-term survival in patients with sarcopenia who underwent living donor liver transplantation. 50 Furthermore, a randomized clinical trial in OLT recipients showed that combined intervention of home-based exercise and dietary modification improved exercise capacity (measured by VO2peak) and self-reported general health. 51 Future studies focusing on interventions to improve muscle mass and long-term clinical outcomes posttransplantation are warranted.
A valuable strength of this study is that CER was measured multiple times over a 6-month period. Utilizing the median of multiple measurements reduces the influence of measurement errors. Other strengths of this study are its sizable population, the long median follow-up of 9.8 years, and a loss to follow-up group composed of only 1 patient.
The current study has some limitations. Previous studies have speculated on the role of nutrition in preventing muscle loss in OLT recipients. 36, 46 Unfortunately, in this study 24 h urinary urea excretion, as a marker for protein intake, was available only in 17.2% of OLT recipients, discarding its utility for analyses. Other limitations are the lack of assessments of muscle mass before and right after transplantation and that data on noncompliance and physical activity were not available. Furthermore, liver biopsies to assess the distribution of fibrosis or cirrhosis were not routinely performed. The fact that our study is a single-center cohort study could limit external validity of its findings.
In conclusion, lower posttransplant urinary CER was inversely associated with an increased risk of both all-cause mortality and graft failure in OLT recipients. In addition, we are the first to show a more than 2.5-fold higher risk for all-cause mortality and a 3-fold higher risk for graft failure in the lowest tertile when compared to the highest tertile of CER. Further research is warranted to investigate possible mechanisms responsible for loss of muscle mass after liver transplantation.
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